The serum biomarker HE4 was introduced as a novel and promising marker by Hellstrom et al. [11] and in 2008 has been cleared by the U.S. Food and Drug Administration for ovarian cancer monitoring. Here, WFDC2 is linked to ovarian carcinoma.